Ovarian Cancer: Second Patient Treated with Novel CAR-T in Trial


The biotechnology company Anixa Biosciences, Inc. together with the Moffitt Cancer Center, issued a press release on May 22nd stating that the second patient had begun treatment as part of the ongoing trial investigating chimeric antigen receptor T-cell therapy (CAR-T) to treat ovarian cancer.

Clinical Trial Phase I (NCT05316129

Anixa’s clinical trial, conducted at the Moffitt Center, will be evaluating safety while at the same time determining the maximum recommended dose of follicle-stimulating hormone receptor T-cells.

All enrolled patients will have disease progression to the extent that they have received two or more treatment interventions that failed. The second patient currently being evaluated is receiving a dose equal to that of the first patient. The same dose will be given to the third patient.

The next three patients will receive an increased dose. Anixa indicated that from that juncture information will be disbursed as warranted.


The engineered T-cells used for Anixa’s therapy are chimeric endocrine receptor T-cells (CER-T) that target endocrine receptors.

CAR-T treatments have had some success against hematological tumors but have not met with success against the type of solid tumors found in ovarian cancers.

One explanation is that in order to effectively avoid healthy cells, CAR-T therapy requires targeting a certain antigen that is present only on cancer cells.

Unlike CAR-T the investigational therapy of the Phase 1 clinical trial sets as its target the follicle-stimulating hormone receptor (FSHR) which is expressed on most ovarian cells.

A New Type of CAR-T

  • The CAR-T therapy uses the patient’s own stem cells (autologous).
  • The cells are engineered and their targets are the follicle-stimulating hormone (chimeric endocrine) receptor (FSHR)
  • FSHR is found on the ovaries’ estrogen-secreting (granulosa) cells.

A hormone receptor is the target (chimeric endocrine) and its binding domain is defined as a protein domain that binds to a specific molecule. Hence the name CER-T (chimeric endocrine receptor T cell)


Rose Duesterwald

Rose Duesterwald

Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email